-
Jan 16, 2025 | 
medicalxpress.com | Mass General Brigham
Osteoarthritis (OA) is a condition that disproportionally affects postmenopausal women, and the millions affected can attest to the pain, reduced mobility and diminished quality of life that comes from this disease. While the hormonal changes associated with menopause have long been known to accelerate the development and progression of OA, a deeper understanding of the biological mechanisms that underlie this correlation is crucial for developing effective treatments.
-
Jan 15, 2025 | 
medicalxpress.com | Mass General Brigham
Red meat consumption is an established risk factor for chronic conditions, including cardiovascular disease and type 2 diabetes. A new study by investigators from Mass General Brigham, Harvard T.H. Chan School of Public Health, and the Broad Institute of MIT and Harvard found that eating greater quantities of red meat, especially in processed forms, increased risk for dementia, too.
-
Jan 15, 2025 | 
xpresschronicle.com | Mass General Brigham
A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ability to mitigate brain damage and improve cognitive functions in mouse models. A forthcoming clinical trial aims to test its efficacy in humans. Most current treatments for Alzheimer’s disease focus on addressing amyloid plaques and tau tangles in the […]Source link Tags: Alzheimers breath cure Gas Transform treatment Xenon
-
Jan 15, 2025 | 
medicalxpress.com | Mass General Brigham
Isotretinoin, commonly referred to as Accutane, is the only approved medical treatment capable of inducing long-term remission of severe acne. Although highly effective, some individuals experience recurrence of acne after a course of treatment. A new study from researchers at Mass General Brigham examined how often acne recurs after isotretinoin and what factors might put patients at risk of acne coming back.
-
Jan 15, 2025 | 
scitechdaily.com | Mass General Brigham
Xenon gas emerges as a promising treatment for Alzheimer’s, showing benefits in preclinical tests such as reducing brain atrophy and enhancing neuron protection, with human trials starting soon. A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ability to mitigate brain damage and improve cognitive functions in mouse models. A forthcoming clinical trial aims to test its efficacy in humans.
-
Jan 14, 2025 | 
medicalxpress.com | Mass General Brigham
As the privatized form of Medicare, Medicare Advantage plans advertise dental, vision, and hearing benefits not covered by traditional Medicare, but a recent analysis found that Medicare Advantage beneficiaries do not typically receive more of these supplemental services than traditional Medicare beneficiaries. Additionally, out-of-pocket spending was similar for most supplemental services. The research led by a team from Mass General Brigham is published in JAMA Network Open.
-
Jan 13, 2025 | 
medicalxpress.com | Mass General Brigham
A study by investigators from Mass General Brigham provides information to empower consumers and policymakers about the degree of processing of the foods available at three large grocery retailers. Using an algorithm, the researchers analyzed the offerings from these stores and assigned a score to foods based on how processed they were. They also analyzed food categories to determine what options are available at different stores. Their results are published in Nature Food.
-
Jan 10, 2025 | 
phys.org | Mass General Brigham
Yang Zhang, Ph.D., and Jinjun Shi, Ph.D., both of the Center for Nanomedicine and Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Women's Hospital, are co-senior authors of a paper published in ACS Nanoscience Au, titled "Lipid Nanoparticle Delivery of mRNA and siRNA for Concurrent Restoration of Tumor Suppressor and Inhibition of Tumorigenic Driver in Prostate Cancer." In this interview, they discuss their research. How would you summarize your study? Most...
-
Jan 9, 2025 | 
medicalxpress.com | Mass General Brigham
Russell W. Jenkins, MD, Ph.D., a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, "TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids".
-
Jan 6, 2025 | 
medicalxpress.com | Mass General Brigham
An FDA-approved medication called glucarpidase could serve as an antidote to kidney toxicity in patients receiving the chemotherapy drug methotrexate (MTX), according to a new study by investigators at Mass General Brigham. Using data from 28 major U.S. cancer centers, the researchers examined the association between glucarpidase treatment—which rapidly clears MTX from the blood—and outcomes of patients with MTX-induced acute kidney injury (AKI).
